Cargando…

Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time-to-onset-based algorithm

PURPOSE: Disproportionality methods measure how unexpected the observed number of adverse events is. Time-to-onset (TTO) methods measure how unexpected the TTO distribution of a vaccine-event pair is compared with what is expected from other vaccines and events. Our purpose is to compare the perform...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Holle, Lionel, Bauchau, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265288/ https://www.ncbi.nlm.nih.gov/pubmed/24038719 http://dx.doi.org/10.1002/pds.3502

Ejemplares similares

The upper bound to the Relative Reporting Ratio—a measure of the impact of the violation of hidden assumptions underlying some disproportionality methods used in signal detection
por: Van Holle, Lionel, et al.
Publicado: (2014)

Use of Logistic Regression to Combine Two Causality Criteria for Signal Detection in Vaccine Spontaneous Report Data
por: Van Holle, Lionel, et al.
Publicado: (2014)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System
por: Huang, Liting, et al.
Publicado: (2021)

Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2019)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV—Priorix-Tetra™) Compared to Separate MMR + V Vaccination
por: Bauchau, Vincent, et al.
Publicado: (2015)

Pharmacoepidemiological considerations in observed‐to‐expected analyses for vaccines
por: Mahaux, Olivia, et al.
Publicado: (2015)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase
por: Noseda, Roberta, et al.
Publicado: (2021)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
por: Gui, Xiujuan, et al.
Publicado: (2023)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017
por: Masuka, Josiah Tatenda, et al.
Publicado: (2019)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

1407. Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
por: Timbrook, Tristan T, et al.
Publicado: (2018)

Immunisation provider experiences with an automated short message service-based active surveillance system for monitoring adverse events following immunisation: A qualitative descriptive study
por: Singh, Gurkamal, et al.
Publicado: (2021)

Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System
por: Barcelos, Flávia Campos, et al.
Publicado: (2019)

Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database
por: Noguchi, Yoshihiro, et al.
Publicado: (2018)

Safety Surveillance of Pneumococcal Vaccine Using Three Algorithms: Disproportionality Methods, Empirical Bayes Geometric Mean, and Tree-Based Scan Statistic
por: Lee, Hyesung, et al.
Publicado: (2020)

Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Frequency of Adverse Events Following Q Fever Immunisation in Young Adults
por: Sellens, Emily, et al.
Publicado: (2018)

Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database
por: Kurian, Anitha, et al.
Publicado: (2018)

Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database
por: Kamath, Ashwin, et al.
Publicado: (2020)

Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System
por: Tatang, Collins, et al.
Publicado: (2021)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

EPH43 Potential Association of Remdesivir and Hyperkalemia: A Disproportionality Analysis in USFDA Adverse Event Reporting System Database
por: Das, A., et al.
Publicado: (2023)

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
por: Liu, Lulu, et al.
Publicado: (2022)

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
por: Kong, Wenqiang, et al.
Publicado: (2023)

Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports
por: Ekhart, Corine, et al.
Publicado: (2022)

Participant-centred active surveillance of adverse events following immunisation: a narrative review
por: Cashman, Patrick, et al.
Publicado: (2017)

Active surveillance study of adverse events following immunisation of children in the Czech Republic
por: Danova, Jana, et al.
Publicado: (2017)

Developing EMR-based algorithms to Identify hospital adverse events for health system performance evaluation and improvement: Study protocol
por: Wu, Guosong, et al.
Publicado: (2022)

Post‐marketing monitoring of intussusception after rotavirus vaccination in Japan
por: Bauchau, Vincent, et al.
Publicado: (2015)

Privacy-Preserving Anonymity for Periodical Releases of Spontaneous Adverse Drug Event Reporting Data: Algorithm Development and Validation
por: Wang, Jie-Teng, et al.
Publicado: (2021)

Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database
por: Li, Hailong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_univ545q0l6h7bd1efv77g8plg